Jump to navigation ☰ Menu Investors Biostage is an evolving leader in regenerative medicine, patient-specific stem cell therapy, and tissue engineering. The company develops customized bioengineered organ implants designed to restore organ function of the esophagus, trachea and bronchus damaged by disease or trauma. Biostage has built a dedicated internal team of materials scientists, engineers and biologists who are working with our external collaborators to bring our products to the patients who need them as quickly as possible. Stock Information OTCQBBSTG Oct 26 Oct 29 Nov 3 Nov 8 Nov 11 Nov 17 Nov 22 $2.25 $2.50 $2.75 $3 $3.25 1dy 1mo 6mo 1yr 5yr Currency in USD. Quote data delayed by at least 15 minutes. Press Releases Nov 15, 2021 Biostage Reports Q3 2021 Financial Results Sep 8, 2021 Biostage™ Appoints Jerry He to Board of Directors and Completes Private Placement of $2.6 Million to Continue Its Clinical Transition Aug 13, 2021 Biostage Reports Q2 2021 Financial Results More > Events Biostage to Host Conference Call to Discuss Third Quarter 2019 Financial Results and Business Update Tuesday, November 12, 2019 9:00am - 10:00am EST Biostage to Host Conference Call to Discuss Second Quarter 2019 Financial Results and Business Update Tuesday, August 13, 2019 9:00am - 10:00am EDT Biostage to Host Conference Call to Discuss First Quarter 2019 Financial Results and Business Update Tuesday, May 14, 2019 9:00am - 10:00am EDT Contact Us Biostage, Inc. 84 October Hill Road Suite 11 Holliston, Massachusetts 01746 United States Phone: 774-233-7300 Toll Free: 855-209-3104 Fax: 774-233-7302 Investor Presentation Download PDF Fact Sheet Privacy Policy Terms of Use Search Contact ©2021 Biostage. All rights reserved.